On Wednesday, April 3, 2019, the U.S. Food and Drug Administration (FDA) announced plans to hold a meeting to discuss its regulatory approach to products that contain cannabis and cannabis-derived compounds, including cannabidiol (CBD). The public hearing, which is scheduled to be held on May 31, 2019, is intended to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling and sale of products containing cannabis and cannabis-derived compounds.
Husch Blackwell attorneys Seth Mailhot and Steve Levine issued a legal alert about this announcement. Find out what this means for the safety, manufacturing, product quality, marketing, labeling and sale of products containing cannabis and cannabis-derived compounds.